Regulatory
October 16, 2026
Regulatory delays can stall a clinical trial before the first sample is tested. A new peer-reviewed analysis in the European Journal of Cancer, which included de-identified operational data contributed by CellCarta, identifies diagnostic regulatory pathways as an underrecognized bottleneck in clinical trial progress, particularly for submissions made in the EU. CellCarta can help avoid this hurdle by connecting regulatory strategy, assay development, and global laboratory execution from day one, so your diagnostic regulatory path is built alongside your clinical development plan, not after it.
